 HR: high-risk cytogenetics or intermediate-risknormal cytogenetics with FLT3 mutation andor any one or more additional clinical risk factors, i.e. total WBC 50x10e9l, FAB subtype M0, M6 or M7, prior myelodysplasia or secondary AML,hepatosplenomegaly, late CR cycle 2, or favorable cytogenetics with late CR cycle 2. 